Better together: biomimetic nanomedicines for high performance tumor therapy
Beilstein Journal of Nanotechnology · 05.08.2025 · 16 · 1246-1276
DOI: 10.3762/bjnano.16.92 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Beilstein Journal of Nanotechnology, online erschienen am 05.08.2025. Verfasst von Imran Shair Mohammad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, City of Hope National Medical Center, 1500 East Duarte Rd., Duarte, California 91010, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The emergence of nanotechnology offers a promising avenue for enhancing cancer treatment outcomes. In this context, biomimetic nanoparticles have emerged as an exciting frontier in the field of biomedicine. These nanoparticles can emulate essential biological functions, drawing from an abundant reservoir of cellular capabilities. This includes engaging in biological binding, precise homing to tumor sites, and interaction with immune cells. These inherent traits endow biomimetic nanoparticles with a suite of intelligent features, including biocompatibility, low immunogenicity, reduced toxicity, immune evasion, prolonged circulation, homotypic binding, enhanced tumor targeting, and the capability of precise delivery. By integrating biologically inspired coatings derived from cell membranes with nanoparticle cores, these carriers become highly versatile vessels for encapsulating a wide array of therapeutic agents. As a result, they are being extensively harnessed for the precise delivery of drugs and genes, underpinning numerous biomedical applications. This discussion delves into the challenges and opportunities presented by biomimetic nanoparticles and offers a comprehensive exploration of their fundamentals and recent breakthroughs, with an eye towards clinical translation. By bridging the gap between scientific innovation and clinical utility, biomimetic nanoparticles hold great promise for advancing the field of cancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, City of Hope National Medical Center, 1500 East Duarte Rd., Duarte, California 91010, USA.
- Nanothera Lab, Drug Application and Research Center (ERFARMA), Erciyes University, 38039, Kayseri, Turkey.
- Faculty of Veterinary and Animal Sciences, Muhammad Nawaz Shareef University of Agriculture, Multan 66000, Pakistan.
- Utah Center for Nanomedicine, University of Utah, Salt Lake City, UT, 84112, USA.
- Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
- Department of Biomedical Engineering, Erciyes University, 38039, Kayseri, Turkey.
ORCID-Profile: Imran Shair Mohammad, Gizem Kursunluoglu, Anup Kumar Patel, Cansu Umran Tunc, Dilek Kanarya, Omer Aydin
Zitieren
APA
Mohammad, I. S., Kursunluoglu, G., Patel, A. K., Ishaq, H. M., Tunc, C. U., Kanarya, D., Rehman, M., Aydin, O., & Lifang, Y. (2025). Better together: biomimetic nanomedicines for high performance tumor therapy. Beilstein Journal of Nanotechnology, 16, 1246-1276. https://doi.org/10.3762/bjnano.16.92
Vancouver
Mohammad IS, Kursunluoglu G, Patel AK, Ishaq HM, Tunc CU, Kanarya D, et al. Better together: biomimetic nanomedicines for high performance tumor therapy. Beilstein Journal of Nanotechnology. 2025;16:1246-1276. doi:10.3762/bjnano.16.92
BibTeX
@article{Mohammad2025,
author = {Mohammad, Imran Shair and Kursunluoglu, Gizem and Patel, Anup Kumar and Ishaq, Hafiz Muhammad and Tunc, Cansu Umran and Kanarya, Dilek and Rehman, Mubashar and Aydin, Omer and Lifang, Yin},
title = {Better together: biomimetic nanomedicines for high performance tumor therapy},
journal = {Beilstein Journal of Nanotechnology},
year = {2025},
volume = {16},
pages = {1246--1276},
doi = {10.3762/bjnano.16.92}
}
EUVIMED